Published in Cancer Epidemiol Biomarkers Prev on August 27, 2010
Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer (2013) 1.01
Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst (2013) 0.88
Properdin and factor h: opposing players on the alternative complement pathway "see-saw". Front Immunol (2013) 0.87
Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. PLoS One (2015) 0.75
Elevated complement factor H levels in asthmatic sputa. J Clin Immunol (2012) 0.75
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
The evolution of Lemierre syndrome: report of 2 cases and review of the literature. Medicine (Baltimore) (2002) 4.33
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res (2011) 3.15
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02
Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. Am J Respir Crit Care Med (2011) 2.93
Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75
Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol (2007) 2.46
Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest (2007) 2.43
Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med (2013) 2.24
Calcium-dependent molecular spring elements in the giant protein titin. Proc Natl Acad Sci U S A (2003) 2.16
Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet (2002) 2.14
Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment. Eur Respir J (2012) 2.07
Nanoliter high throughput quantitative PCR. Nucleic Acids Res (2006) 2.00
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol (2014) 1.99
[Use of indwelling pleural catheter in the outpatient management of recurrent malignant pleural effusion]. Arch Bronconeumol (2009) 1.99
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol (2013) 1.86
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov (2013) 1.85
Anemia and inflammation in COPD. Chest (2005) 1.83
Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta (2010) 1.73
Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration (2005) 1.70
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement. Int J Cardiol (2006) 1.58
Automatic pressure titration with APAP is as effective as manual titration with CPAP in patients with obstructive sleep apnea. Respiration (2007) 1.57
Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med (2015) 1.55
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. Genome Biol (2008) 1.52
Early calcification of the aortic Mitroflow pericardial bioprosthesis in the elderly. Interact Cardiovasc Thorac Surg (2009) 1.52
Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene (2004) 1.49
A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol (2013) 1.47
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. J Virol (2002) 1.42
Nebulin alters cross-bridge cycling kinetics and increases thin filament activation: a novel mechanism for increasing tension and reducing tension cost. J Biol Chem (2009) 1.41
Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res (2012) 1.39
[Early detection of lung cancer: the right time]. Med Clin (Barc) (2002) 1.39
Modified technique for obtaining mediastinal samples with endobronchial ultrasound-guided transbronchial needle aspiration: results from a prospective observational study. Arch Bronconeumol (2012) 1.39
Associations of daily walking activity with biomarkers related to cardiac distress in patients with chronic obstructive pulmonary disease. Respiration (2012) 1.38
Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score. Dtsch Arztebl Int (2017) 1.34
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog (2004) 1.32
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol (2012) 1.30
Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res (2004) 1.29
Septic thrombophlebitis: diagnosis and management. Am J Cardiovasc Drugs (2006) 1.24
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res (2004) 1.24
Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med (2005) 1.22
Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer (2003) 1.22
Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema. Eur Respir J (2011) 1.22
Complement inhibition in cancer therapy. Semin Immunol (2013) 1.20
Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. Am J Cardiol (2006) 1.20
Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res (2004) 1.19
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol (2011) 1.17
Diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-analysis. Respiration (2014) 1.16
Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema. Int J Chron Obstruct Pulmon Dis (2012) 1.15
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J (2003) 1.15
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol (2009) 1.14
Use of the Dumon Y-stent in the management of malignant disease involving the carina: a retrospective review of 86 patients. Chest (2004) 1.14
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer (2010) 1.12
Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia (2007) 1.12
Alternative splicing in lung cancer. J Thorac Oncol (2009) 1.12
Distribution of respiratory mucin proteins in human nasal mucosa. Laryngoscope (2003) 1.11
Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol (2007) 1.11
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem (2003) 1.10
MuRF1 is a muscle fiber-type II associated factor and together with MuRF2 regulates type-II fiber trophicity and maintenance. J Struct Biol (2010) 1.10
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol (2007) 1.09
A gene-alteration profile of human lung cancer cell lines. Hum Mutat (2009) 1.09
Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J (2012) 1.09
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J (2005) 1.09
Remote estimation of blood pulse pressure via temporal tracking of reflected secondary speckles pattern. J Biomed Opt (2011) 1.06
Telomeres and telomerase in lung cancer. J Thorac Oncol (2008) 1.06
Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol (2012) 1.06
Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol (2011) 1.06
Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema. Respiration (2012) 1.06
A nanoliter fluidic platform for large-scale single nucleotide polymorphism genotyping. Biotechniques (2009) 1.05
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer (2010) 1.04
Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med (2012) 1.04
Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist (2011) 1.04
Simultaneous remote extraction of multiple speech sources and heart beats from secondary speckles pattern. Opt Express (2009) 1.03
Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol (2005) 1.02
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol (2007) 1.02
Substance P expression in TRPV1 and trkA-positive dorsal root ganglion neurons innervating the mouse lung. Respir Physiol Neurobiol (2004) 1.01
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther (2009) 1.01
Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med (2008) 1.00
Dynamic distribution of muscle-specific calpain in mice has a key role in physical-stress adaptation and is impaired in muscular dystrophy. J Clin Invest (2010) 0.99
Expression of distinct classes of titin isoforms in striated and smooth muscles by alternative splicing, and their conserved interaction with filamins. J Mol Biol (2006) 0.99
Evaluation of micro-CT for emphysema assessment in mice: comparison with non-radiological techniques. Eur Radiol (2010) 0.99